New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:52 EDTSGMO, IDRA, BLUE, AGTC, ISIS, CLDN, ARWR, SRPT, INO, BMRN, ALNYPiper Jaffray to hold a symposium
GenomeRX Symposium to be held in New York on June 23.
News For AGTC;ALNY;ARWR;BLUE;BMRN;CLDN;IDRA;INO;ISIS;SGMO;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 29, 2015
08:36 EDTBMRNBioMarin announces FDA acceptance of drisapersen NDA
Subscribe for More Information
07:05 EDTSRPTSarepta completes NDA submission to FDA for eteplirsen
Subscribe for More Information
07:03 EDTSRPTSarepta secures $40M in debt financing
Sarepta Therapeutics announced that it entered into a credit and security agreement with Midcap Financial, a middle market-focused, specialty finance firm, that establishes a senior secured term loan facility that allows Sarepta to borrow up to $40M at an annual rate of 7.75%, with a maturity of June 2018, subject to certain conditions and other applicable fees. Sarepta has drawn down $20M under the facility and has the right to repay all borrowed funds and terminate the facility at any time.
June 26, 2015
11:00 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT AGO CRC WMB AMZN CMG TRIP ZTS AET MBI
10:02 EDTCLDNCelladon discloses further 50% workforce reduction
In a regulatory filing, Celladon disclosed that its board approved an additional 50% reduction of the company's 17 current remaining full-time employees who were not included in the workforce reduction announced on April 30, 2015. The company expects that this group of employees, which constitutes the remainder of the company’s research and development staff, will be separated from the company during the third quarter of 2015. The company estimates that it will incur incremental aggregate cash charges of approximately $1.33M associated with this workforce reduction. This reduction is in addition to the previously announced 50% workforce reduction announced on April 30, 2015.
09:10 EDTCLDNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Finish Line (FINL), up 6.5%... Nike (NKE), up 3.2%. ALSO HIGHER: GigaMedia (GIGM), up 14.6% after agreeing to acquire 70% equity interest in Strawberry Cosmetics. DOWN AFTER EARNINGS: Micron Technology (MU), down 14.8%. ALSO LOWER: Celladon (CLDN), down 42.7% after planning to suspend further R&D of MYDICAR program... Real Goods Solar (RGSE), down 18.4% after raising $5M in a common stock and warrant offering... SanDisk (SNDK), down 3.3% after Micron Technology reports quarterly results... Alder Biopharmaceuticals (ALDR), down 2.6% after 4.49M share Secondary priced at $44.50... Sotherly Hotels (SOHO), down 2% after 3M share Secondary priced at $7.11.
06:02 EDTCLDNCelladon plans to suspend further R&D of MYDICAR program
Subscribe for More Information
June 25, 2015
16:03 EDTBMRNBioMarin announces EMA validates MAA for drisapersen for treatment of DMD
Subscribe for More Information
12:59 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
June 24, 2015
09:07 EDTBLUECAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:06 EDTBLUEbluebird bio 2.94M share Spot Secondary priced at $170.00
Subscribe for More Information
June 23, 2015
18:04 EDTISISIsis Pharma granted FDA orphan status for treatment of familial chylomicronemia
Subscribe for More Information
16:18 EDTALNYAlnylam weakness a buying opportunity, says Deutsche Bank
Deutsche Bank said Alnylam's Phase 1 AT-3 conference presentation update was positive, as expected, supporting safety and efficacy. The firm's analyst said weakness could be due to fast money selling and recommends buying shares on weakness.
16:01 EDTBLUEbluebird bio files to sell $400M in common stock
Subscribe for More Information
14:31 EDTALNYAlnylam reports new positive clinical data for ALN-AT3
Subscribe for More Information
08:58 EDTISISIsis Pharmaceuticals shares not reflecting SMA data, says Needham
Subscribe for More Information
07:49 EDTBMRNPTC Therapeutics risk lowered by symposium, says Oppenheimer
Subscribe for More Information
07:25 EDTBMRNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
08:03 EDTBLUEKite Pharma, bluebird bio announce strategic collaboration
Subscribe for More Information
07:01 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx in Phase 2 study
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use